GRAIL (a liquid biopsy test using cell-free DNA methylation patterns) can detect cancer presence and estimate origin organ; it has low sensitivity (poor at detecting stage 1-2 cancer, ~20% for most histologies) but high specificity (good at confirming absence of cancer); the positive and negative predictive values depend on pretest probability (cancer prevalence in the population tested).